ATNX Athenex Inc.

11.06
-0.2  -2%
Previous Close 11.26
Open 11.24
Price To Book 5.32
Market Cap 741279888
Shares 67,023,498
Volume 244,963
Short Ratio
Av. Daily Volume 271,873

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 preliminary data showed 50% PR and 50% SD among first 12 patients.
Oraxol
Breast cancer
Phase 1b data noted 2/6 and 3/6 PRs in first two cohorts.
Oraxol and CYRAMZA (Ramucirumab)
Gastric cancer
Phase 3 data released July 26, 2018. Primary endpoint met.
KX-01 (KX2-391) Ointment
Actinic keratosis
Phase 3 data due mid-2019.
Oraxol
Metastatic breast cancer
Clinical trials to commence 2019.
Oral Eribulin
Phase 1/2 initiation announced November 26, 2018.
Oraxol and pembrolizumab (Keytruda)
Solid Tumors

Latest News

  1. Athenex Announces Appointment of John Koh as a New Board Member
  2. Weekly CEO Buys Highlight
  3. Athenex Announces Appointment of Jordan S. Kanfer to Board of Directors
  4. Athenex Inc (ATNX) CEO and Chairman of the Board Johnson Yiu Nam Lau Bought $124,000 of Shares
  5. Athenex Announces Appointment of Dr. Daniel Von Hoff as Chairman of the Scientific Advisory Board of Axis Therapeutics Limited
  6. New Research Coverage Highlights UnitedHealth Group, Ultragenyx Pharmaceutical, Navistar International, REGENXBIO, Par Pacific, and Athenex — Consolidated Revenues, Company Growth, and Expectations for 2019
  7. Athenex Announces Xiangxue Life Sciences Receives IND Allowance from China’s National Medical Products Administration for Cancer Immunotherapy Drug Candidate
  8. Athenex Announces Expansion of Board of Directors
  9. Edited Transcript of ATNX earnings conference call or presentation 11-Mar-19 12:30pm GMT
  10. The moment Athenex executives and investors have been waiting for is almost here
  11. SunGen Pharma and Athenex Pharmaceutical Division Announce Busulfan Injection Product Launch
  12. Athenex, Inc. (ATNX) Q4 2018 Earnings Conference Call Transcript
  13. Athenex: 4Q Earnings Snapshot
  14. Athenex, Inc. Announces Fourth Quarter and Year Ended December 31, 2018 Financial Results and Provides Corporate Update
  15. Athenex to Present Preclinical Data of Oraxol in the Treatment of Angiosarcoma at the American Association for Cancer Research Annual Meeting 2019
  16. Athenex Regains Rights to KX2-391 in China
  17. Almirall and Athenex Announce Positive Topline Results from Two Phase III Studies of KX2-391 Ointment 1% Featured in Late Breaker Program at the 2019 American Academy of Dermatology Annual Meeting
  18. Shares of Athenex up 3.8% after Phase 3 studies for actinic keratosis treatment meet primary endpoints
  19. Athenex Announces Positive Topline Results from Two Phase III Studies of KX2-391 Ointment 1% Featured in Late Breaker Program at the 2019 American Academy of Dermatology Annual Meeting